首页> 外文期刊>Journal of Biomedical Semantics >Therapeutic indications and other use-case-driven updates in the drug ontology: anti-malarials, anti-hypertensives, opioid analgesics, and a large term request
【24h】

Therapeutic indications and other use-case-driven updates in the drug ontology: anti-malarials, anti-hypertensives, opioid analgesics, and a large term request

机译:药物本体中的治疗指征和其他由用例驱动的更新:抗疟疾,抗高血压药,阿片类镇痛药和长期需求

获取原文
           

摘要

BackgroundThe Drug Ontology (DrOn) is an OWL2-based representation of drug products and their ingredients, mechanisms of action, strengths, and dose forms. We originally created DrOn for use cases in comparative effectiveness research, primarily to identify historically complete sets of United States National Drug Codes (NDCs) that represent packaged drug products, by the ingredient(s), mechanism(s) of action, and so on contained in those products. Although we had designed DrOn from the outset to carefully distinguish those entities that have a therapeutic indication from those entities that have a molecular mechanism of action, we had not previously represented in DrOn any particular therapeutic indication. ResultsIn this work, we add therapeutic indications for three research use cases: resistant hypertension, malaria, and opioid abuse research. We also added mechanisms of action for opioid analgesics and added 108 classes representing drug products in response to a large term request from the Program for Resistance, Immunology, Surveillance and Modeling of Malaria in Uganda (PRISM) project. The net result is a new version of DrOn, current to May 2016, that represents three major therapeutic classes of drugs and six new mechanisms of action. ConclusionsA therapeutic indication of a drug product is represented as a therapeutic function in DrOn. Adverse effects of drug products, as well as other therapeutic uses for which the drug product was not designed are dispositions. Our work provides a framework for representing additional therapeutic indications, adverse effects, and uses of drug products beyond their design. Our work also validated our past modeling decisions for specific types of mechanisms of action, namely effects mediated via receptor and/or enzyme binding. DrOn is available at: http://purl.obolibrary.org/obo/dron.owl . A smaller version without NDCs is available at: http://purl.obolibrary.org/obo/dron/dron-lite.owl
机译:背景药物本体论(DrOn)是一种基于OWL2的药物产品及其成分,作用机理,强度和剂型的表示形式。我们最初是为比较有效性研究中的用例创建DrOn的,主要是通过成分,作用机理等来识别代表包装药品的美国国家药品法规(NDC)的历史完整集。这些产品中包含的内容。尽管我们从一开始就设计了DrOn来仔细地区分具有治疗指征的实体和具有分子作用机制的实体,但我们以前并未在DrOn中代表任何特定的治疗指征。结果在这项工作中,我们为三种研究用例增加了治疗适应症:抵抗性高血压,疟疾和阿片类药物滥用研究。我们还增加了阿片类镇痛药的作用机理,并增加了108类代表药品的类,以响应乌干达抗疟,免疫学,监视和建模计划(PRISM)项目的长期要求。最终结果是DrOn的最新版本,目前有效期至2016年5月,代表了三种主要的药物治疗类别和六种新的作用机制。结论药物的治疗适应症表现为DrOn的治疗功能。药物的不良作用以及未设计该药物的其他治疗用途均属于这种情况。我们的工作提供了一个框架,用于表示超出其设计范围的其他治疗适应症,不良反应和药物使用。我们的工作还验证了我们过去针对特定类型的作用机制(即通过受体和/或酶结合介导的作用)的建模决策。 DrOn可从以下网站获得:http://purl.obolibrary.org/obo/dron.owl。没有NDC的较小版本可以在以下位置找到:http://purl.obolibrary.org/obo/dron/dron-lite.owl

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号